retatrutide phase 2 trial obesity nejm 2023 results Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 retatrutide triple agonist glp-1 gip

CM indicates cardiomyocyte

Copper IUD (Paragard)

Unlike full-length growth hormone, AOD9604 enables researchers to investigate biological activities associated with this specific peptide fragment while examining receptor interactions, intracellular signaling pathways, peptide engineering, and molecular pharmacology under controlled laboratory conditions

Because direct human data on retatrutide and alcohol is still limited, it is best to be cautious

Additionally, while Tirzepatide is highly effective in facilitating substantial weight loss it will be most effective when it is used as one component of a broader medical weight management plan